

Clinical Resource Tool



Click on the links below



Clinical Management Guidelines



2023: Clinical Assessment and Management of Nonalcoholic Fatty Liver Disease

<https://tinyurl.com/2023-AASLD>

2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease

<https://tinyurl.com/2019-ACC-AHA>



Patient Resources



National Institute of Diabetes and Digestive and Kidney Diseases

Nonalcoholic Fatty Liver Disease (NAFLD) & NASH

<https://tinyurl.com/NIDDK-NAFLD-NASH>



Nonalcoholic Fatty Liver Disease (NAFLD)

<https://tinyurl.com/LiverFound-NAFLD>



Nonalcoholic Fatty Liver Disease (NAFLD)

<https://tinyurl.com/AmCollGI-NAFLD>

Nonalcoholic Steatohepatitis (NASH)

<https://tinyurl.com/LiverFound-NASH>



The NASH Education Program

<https://www.the-nash-education-program.com/>



Additional Readings

Mortality in Biopsy-Confirmed Nonalcoholic Fatty Liver Disease: Results from a Nationwide Cohort

Simon TG, et al. *Gut*. 2021 Jul;70(7):1375-1382.

Women Have a Lower Risk of Nonalcoholic Fatty Liver Disease but a Higher Risk of Progression vs Men: A Systematic Review and Meta-analysis

Balakrishnan M, et al. *Clin Gastroenterol Hepatol*. 2021 Jan;19(1):61-71.e15.

Community Socioeconomic Deprivation Predicts Nonalcoholic Steatohepatitis

Giammarino AM, et al. *Hepatol Commun*. 2022 Mar;6(3):550-560.

Topline Results From a New Analysis of the REGENERATE Trial of Obeticholic Acid for the Treatment of Nonalcoholic Steatohepatitis

Sanyal AJ, et al. NASH-TAG Conference 2023. Abstract #26. Available at:

<https://tinyurl.com/REGEN-OCA-NASH>

Current Treatment Paradigms and Emerging Therapies for NAFLD/NASH

Raza S, et al. *Front Biosci (Landmark Ed)*. 2021 January 01;26:206-237

A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH

Francque SM, et al. *N Engl J Med*. 2021;385:1547-58.